Cargando…
Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
BACKGROUND: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI). OBJECTIVE: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegene...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597964/ https://www.ncbi.nlm.nih.gov/pubmed/31259306 http://dx.doi.org/10.3233/ADR-190109 |
_version_ | 1783430674142724096 |
---|---|
author | Manzano Palomo, Maria Sagrario Anaya Caravaca, Belen Balsa Bretón, Maria Angeles Castrillo, Sergio Muñiz Vicente, Asuncion de la Morena Castro Arce, Eduardo Alves Prez, María Teresa |
author_facet | Manzano Palomo, Maria Sagrario Anaya Caravaca, Belen Balsa Bretón, Maria Angeles Castrillo, Sergio Muñiz Vicente, Asuncion de la Morena Castro Arce, Eduardo Alves Prez, María Teresa |
author_sort | Manzano Palomo, Maria Sagrario |
collection | PubMed |
description | BACKGROUND: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI). OBJECTIVE: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegeneration biomarkers. METHODS: This cohort study was carried out from June 2015 through December 2016 in the Neurology Department, Infanta Cristina Hospital, Madrid, Spain. MCI-HR-AD were recruited using Petersen criteria, neuropsychology (NPS), and (18)F-FDG PET scans to confirm the high risk of progression to dementia with one year of follow-up. Age, sex, vascular risk factors (VRF), and NPS values (Barcelona brief version) were analyzed. (18)F-FDG PET scans were analyzed as a visual procedure. The study was approved by the Research Committee of ICH. Statistical analysis was made with SPSS 22.0 version. RESULTS: Subjects included 43 MCI patients (58.5% women; mean age 69.78±7.89): 17 receiving Souvenaid(®) treatment (ST), 24 receiving no treatment (WT) and 2 who withdrew. No differences were seen in VRF, only hypercholesterolemia, and were less prevalent in the ST group (p = 0.002). The rate of progression to dementia was 48.8% (no differences between groups, p = 0.654). A second round of (18)F-FDG PET scans showed a significance worsening of glucose metabolism in WT (p = 0.001) versus ST, in which it was low (p = 0.050). For NPS testing, there was a significant worsening in memory performance in the WT group (p = 0.011) and a stabilization in ST (p = 0.083), as well as in executive functions and attention (worsening in WT, p = 0.014). For the Subjective Changing Scale (SCS), caregivers indicated a stabilization/improvement in ST (p = 0.017). CONCLUSION: Souvenaid had a significant effect on several cognitive domains, and on SCS in patients with MCI-HR-AD. Its intervention had an impact on preservation on (18)F-FDG PET scans. |
format | Online Article Text |
id | pubmed-6597964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-65979642019-06-28 Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans Manzano Palomo, Maria Sagrario Anaya Caravaca, Belen Balsa Bretón, Maria Angeles Castrillo, Sergio Muñiz Vicente, Asuncion de la Morena Castro Arce, Eduardo Alves Prez, María Teresa J Alzheimers Dis Rep Research Report BACKGROUND: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI). OBJECTIVE: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegeneration biomarkers. METHODS: This cohort study was carried out from June 2015 through December 2016 in the Neurology Department, Infanta Cristina Hospital, Madrid, Spain. MCI-HR-AD were recruited using Petersen criteria, neuropsychology (NPS), and (18)F-FDG PET scans to confirm the high risk of progression to dementia with one year of follow-up. Age, sex, vascular risk factors (VRF), and NPS values (Barcelona brief version) were analyzed. (18)F-FDG PET scans were analyzed as a visual procedure. The study was approved by the Research Committee of ICH. Statistical analysis was made with SPSS 22.0 version. RESULTS: Subjects included 43 MCI patients (58.5% women; mean age 69.78±7.89): 17 receiving Souvenaid(®) treatment (ST), 24 receiving no treatment (WT) and 2 who withdrew. No differences were seen in VRF, only hypercholesterolemia, and were less prevalent in the ST group (p = 0.002). The rate of progression to dementia was 48.8% (no differences between groups, p = 0.654). A second round of (18)F-FDG PET scans showed a significance worsening of glucose metabolism in WT (p = 0.001) versus ST, in which it was low (p = 0.050). For NPS testing, there was a significant worsening in memory performance in the WT group (p = 0.011) and a stabilization in ST (p = 0.083), as well as in executive functions and attention (worsening in WT, p = 0.014). For the Subjective Changing Scale (SCS), caregivers indicated a stabilization/improvement in ST (p = 0.017). CONCLUSION: Souvenaid had a significant effect on several cognitive domains, and on SCS in patients with MCI-HR-AD. Its intervention had an impact on preservation on (18)F-FDG PET scans. IOS Press 2019-05-03 /pmc/articles/PMC6597964/ /pubmed/31259306 http://dx.doi.org/10.3233/ADR-190109 Text en © 2019 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Report Manzano Palomo, Maria Sagrario Anaya Caravaca, Belen Balsa Bretón, Maria Angeles Castrillo, Sergio Muñiz Vicente, Asuncion de la Morena Castro Arce, Eduardo Alves Prez, María Teresa Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans |
title | Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans |
title_full | Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans |
title_fullStr | Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans |
title_full_unstemmed | Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans |
title_short | Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans |
title_sort | mild cognitive impairment with a high risk of progression to alzheimer’s disease dementia (mci-hr-ad): effect of souvenaid(®) treatment on cognition and (18)f-fdg pet scans |
topic | Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597964/ https://www.ncbi.nlm.nih.gov/pubmed/31259306 http://dx.doi.org/10.3233/ADR-190109 |
work_keys_str_mv | AT manzanopalomomariasagrario mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans AT anayacaravacabelen mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans AT balsabretonmariaangeles mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans AT castrillosergiomuniz mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans AT vicenteasunciondelamorena mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans AT castroarceeduardo mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans AT alvesprezmariateresa mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans |